TABLE 1.
Selected laboratory values
| Test name (units as applicable) | Result | Reference interval |
|---|---|---|
| CBC (initial presentation) | ||
| WBC (K/μL) | 5.8 | 3.2–10.6 |
| RBC (M/ μL) | 5.07 | 3.98–5.98 |
| Hemoglobin (g/dL) | 15.0 | 12.5–18.0 |
| Hematocrit (%) | 42.2 | 36.9–52.1 |
| MCV (fL) | 83.2 | 80.6–97.6 |
| MCHC (g/dL) | 35.5 | 33.4–35.3 |
| Platelets (K/μL) | 74 | 140–440 |
| Hemostasis Tests (initial presentation) | ||
| D‐dimer (ng/mL FEU) | 15 109 | 0–499 |
| PT (s) | 12.7 | 10–13 |
| aPTT (s) | 31.8 | 25.1–36.5 |
| Fibrinogen (mg/dL) | 254 | 150–430 |
| Thrombophilia Tests a | ||
| Prothrombin G20210A mutation | Not detected | Not detected |
| Factor V Leiden mutation | Not detected | Not detected |
| Lupus anticoagulant interpretation | Not detected | Not detected |
| Anticardiolipin IgG (GPL) | 5 | 0–14 |
| Anticardiolipin IgM (MPL) | 6 | 0–12 |
| β2‐glycoprotein 1 IgG (SGU) | 0 | 0–20 |
| β2‐glycoprotein 1 IgM (SMU) | 5 | 0–20 |
| SARS‐CoV‐2 Test | ||
| PCR | Not detected (nasopharyngeal swab specimen) | Not detected |
| VITT Tests (prior to IVIG therapy) | ||
| Anti‐PF4 antibody (OD) | 3.323 | ≤0.399 |
| Serotonin release assay | Positive |
Negative |
| P‐selectin expression assay | Positive |
Negative |
a
Protein C activity (clot‐based), protein S activity, and antithrombin activity not appropriate at the time of acute thrombosis and during rivaroxaban treatment.